Ascending Multi-Dose Clinical Trial to Assess the Pharmacokinetics Efficacy of SM-88 Oral Administration in Breast Cancer Subjects

Trial Profile

Ascending Multi-Dose Clinical Trial to Assess the Pharmacokinetics Efficacy of SM-88 Oral Administration in Breast Cancer Subjects

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Jun 2016

At a glance

  • Drugs SM 88 (Primary)
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Sponsors Synergy Pharmaceuticals Inc; Tyme Technologies
  • Most Recent Events

    • 01 Jun 2016 Planned number of patients changed from 18 to 50.
    • 01 Jun 2016 Planned End Date changed from 1 Oct 2016 to 1 Oct 2019.
    • 01 Jun 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top